Leukemia Inhibitory Factor

Subscribe to Selected New Research on Leukemia Inhibitory Factor

354 relevant articles (5 outcomes, 31 trials/studies) found for this Bio-Agent

Description: An INTERLEUKIN-6 related cytokine that exhibits pleiotrophic effects on many physiological systems that involve cell proliferation, differentiation, and survival. Leukemia inhibitory factor binds to and acts through the LIF RECEPTOR.

Also Known As:

AM424; AMRAD Brand of Recombinant Human Leukemia Inhibitory Factor; Cholinergic Differentiation Factor; D Factor (Leukemia Inhibitory Factor); Differentiation-Stimulating Factor; Emfilermin; Myeloid Differentiation-Stimulating Factor; Differentiation Factor, Cholinergic; Differentiation Stimulating Factor; Differentiation-Stimulating Factor, Myeloid; Inhibitory Factor, Leukemia; Myeloid Differentiation Stimulating Factor

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kilpatrick, Trevor J: 3 articles (04/2008 - 06/2003)
2.	Cheema, Surindar S: 3 articles (09/2006 - 08/2003)
3.	Melmed, Shlomo: 3 articles (03/2006 - 05/2002)
4.	Park, Jong-In: 3 articles (02/2005 - 02/2005)
5.	Nelkin, Barry D: 3 articles (02/2005 - 02/2005)
6.	Dimitriadis, Evdokia: 2 articles (08/2008 - 02/2006)
7.	Salamonsen, Lois A: 2 articles (08/2008 - 02/2006)
8.	Emery, Ben: 2 articles (04/2008 - 05/2006)
9.	Marriott, Mark P: 2 articles (04/2008 - 05/2006)
10.	Butzkueven, Helmut: 2 articles (04/2008 - 05/2006)

Related Diseases

1.	Myocardial Infarction 10/26/2007 - "The aim of the present study was to investigate (1) the effect and underlying signal transduction pathways of leukemia inhibitory factor (LIF) and bone-morphogenic protein-2 (BMP-2)-induced mouse ES cell (mES-D3 line) differentiation into cardiomyocytes (CMC) and (2) the efficacy of CMC precommitted mES cells for functional and anatomical cardiac repair in surgically-induced mouse acute myocardial infarction (AMI) model. " 12/01/2004 - "CONCLUSIONS: Myocardial gene transfer of leukemia inhibitory factor preserved cardiac tissue, geometry, and function after myocardial infarction in rats." 08/12/2003 - "Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction." Order ALL the reference details at left...
2.	Endotoxemia 04/01/1992 - "Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: synergistic effect with interleukin 1 and tumor necrosis factor." Order ALL the reference details at left...
3.	Experimental Autoimmune Neuritis 12/01/2002 - "Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis." Order ALL the reference details at left...
4.	Nephritis 01/01/1998 - "In particular administration of interleukin 4, interleukin 1 receptor antagonist, leukemia inhibitory factor, or interleukin 10 has been shown to be effective in the treatment of nephrotoxic nephritis. " Order ALL the reference details at left...
5.	Glomerulonephritis 12/01/1996 - "Leukemia inhibitory factor ameliorates experimental anti-GBM Ab glomerulonephritis." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Interleukin-4 (Interleukin 4)
3.	Interleukin-1 (Interleukin 1)
4.	Interleukin-10 (Interleukin 10)
5.	Interleukin-1 Receptors (Interleukin 1 Receptor)
6.	antiglomerular basement membrane antibody
7.	Interleukin-6 (Interleukin 6)
8.	Leukemia Inhibitory Factor
9.	Interferon-gamma (Interferon, gamma)
10.	Interleukins

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Injections
3.	Stem Cell Transplantation
4.	Axotomy
5.	Homologous Transplantation (Allograft)

Best Treatments:
Research Summary Report
on Myocardial Infarction

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2308 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>